Arizona State Retirement System Sells 120 Shares of Glaukos Co. (NYSE:GKOS)

Arizona State Retirement System cut its holdings in shares of Glaukos Co. (NYSE:GKOS) by 0.9% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 12,920 shares of the medical instruments supplier’s stock after selling 120 shares during the period. Arizona State Retirement System’s holdings in Glaukos were worth $1,027,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in GKOS. Tower Research Capital LLC TRC raised its holdings in shares of Glaukos by 257.8% in the 1st quarter. Tower Research Capital LLC TRC now owns 1,238 shares of the medical instruments supplier’s stock valued at $62,000 after purchasing an additional 892 shares during the period. Captrust Financial Advisors raised its holdings in shares of Glaukos by 17.1% in the 2nd quarter. Captrust Financial Advisors now owns 1,738 shares of the medical instruments supplier’s stock valued at $79,000 after purchasing an additional 254 shares during the period. CWM LLC raised its holdings in shares of Glaukos by 309.5% in the 3rd quarter. CWM LLC now owns 1,384 shares of the medical instruments supplier’s stock valued at $104,000 after purchasing an additional 1,046 shares during the period. State of Wyoming raised its holdings in shares of Glaukos by 28.0% in the 2nd quarter. State of Wyoming now owns 1,565 shares of the medical instruments supplier’s stock valued at $111,000 after purchasing an additional 342 shares during the period. Finally, Allspring Global Investments Holdings LLC raised its holdings in shares of Glaukos by 17.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,827 shares of the medical instruments supplier’s stock valued at $137,000 after purchasing an additional 270 shares during the period. 99.04% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on GKOS shares. Wells Fargo & Company upped their target price on shares of Glaukos from $83.00 to $103.00 and gave the company an “overweight” rating in a report on Thursday, February 22nd. JPMorgan Chase & Co. raised shares of Glaukos from a “neutral” rating to an “overweight” rating and upped their target price for the company from $66.00 to $91.00 in a report on Thursday, December 21st. Truist Financial reissued a “buy” rating and issued a $110.00 price target on shares of Glaukos in a report on Monday, April 8th. Stifel Nicolaus reissued a “buy” rating and issued a $110.00 price target on shares of Glaukos in a report on Wednesday, April 3rd. Finally, Piper Sandler increased their price target on shares of Glaukos from $90.00 to $105.00 and gave the company an “overweight” rating in a report on Friday, December 22nd. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Glaukos has an average rating of “Moderate Buy” and a consensus target price of $99.80.

Glaukos Stock Performance

Shares of NYSE:GKOS opened at $96.81 on Tuesday. The company’s 50 day moving average price is $91.77 and its two-hundred day moving average price is $80.18. Glaukos Co. has a 12-month low of $45.38 and a 12-month high of $102.33. The firm has a market cap of $4.79 billion, a PE ratio of -34.82 and a beta of 1.08. The company has a quick ratio of 4.78, a current ratio of 5.34 and a debt-to-equity ratio of 0.77.

Glaukos (NYSE:GKOS) last announced its earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.07). Glaukos had a negative return on equity of 22.67% and a negative net margin of 42.79%. The business had revenue of $82.40 million for the quarter, compared to analyst estimates of $81.00 million. During the same quarter in the previous year, the company earned ($0.53) EPS. The business’s revenue for the quarter was up 15.7% on a year-over-year basis. Equities research analysts predict that Glaukos Co. will post -2.18 earnings per share for the current year.

Insiders Place Their Bets

In other Glaukos news, Director Gilbert H. Kliman sold 5,000 shares of the stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $88.25, for a total transaction of $441,250.00. Following the transaction, the director now owns 30,620 shares in the company, valued at approximately $2,702,215. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, Director Mark J. Foley sold 4,560 shares of Glaukos stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $92.87, for a total value of $423,487.20. Following the transaction, the director now directly owns 33,220 shares of the company’s stock, valued at $3,085,141.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gilbert H. Kliman sold 5,000 shares of Glaukos stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $88.25, for a total transaction of $441,250.00. Following the completion of the transaction, the director now directly owns 30,620 shares in the company, valued at $2,702,215. The disclosure for this sale can be found here. Insiders have sold a total of 243,464 shares of company stock worth $22,959,418 in the last quarter. Corporate insiders own 7.80% of the company’s stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.